Doxorubicin + docetaxel-, illetóleg doxorubicin + cyclophosphamid-kezeléssel elérhetó eredmények távoli áttétet adó emlórákban.

Translated title of the contribution: Effectiveness of doxorubicin-docetaxel or doxorubicin-cyclophosphamide combination in advanced breast cancer with distant metastasis

J. Szántó, T. Pintér, J. Szántó

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Between June 1996 and March 1998 a multinational multicentric phase III randomised comparative study was made for comparing 1. the effectiveness, 2. the adverse events and 3. the quality of life of two combinations i.e. DD versus DC. 18 patients were treated with DD and 15 patients with DC. Age, tumour stage, visceral involvement, receptor status were well matched in the two groups. Good partial remission was obtained in 10 patients treated with DD whereas only seven remissions were seen in the DC arm. Response duration was similar in the 2 arms. No difference in adverse events was observed.

Original languageHungarian
Pages (from-to)723-726
Number of pages4
JournalOrvosi Hetilap
Volume142
Issue number14
Publication statusPublished - Apr 8 2001

Fingerprint

docetaxel
Doxorubicin
Cyclophosphamide
Breast Neoplasms
Neoplasm Metastasis
Quality of Life
Neoplasms

ASJC Scopus subject areas

  • Medicine(all)

Cite this

@article{6f34256831cb4add9a0d796324fed670,
title = "Doxorubicin + docetaxel-, illet{\'o}leg doxorubicin + cyclophosphamid-kezel{\'e}ssel el{\'e}rhet{\'o} eredm{\'e}nyek t{\'a}voli {\'a}tt{\'e}tet ad{\'o} eml{\'o}r{\'a}kban.",
abstract = "Between June 1996 and March 1998 a multinational multicentric phase III randomised comparative study was made for comparing 1. the effectiveness, 2. the adverse events and 3. the quality of life of two combinations i.e. DD versus DC. 18 patients were treated with DD and 15 patients with DC. Age, tumour stage, visceral involvement, receptor status were well matched in the two groups. Good partial remission was obtained in 10 patients treated with DD whereas only seven remissions were seen in the DC arm. Response duration was similar in the 2 arms. No difference in adverse events was observed.",
author = "J. Sz{\'a}nt{\'o} and T. Pint{\'e}r and J. Sz{\'a}nt{\'o}",
year = "2001",
month = "4",
day = "8",
language = "Hungarian",
volume = "142",
pages = "723--726",
journal = "Orvosi Hetilap",
issn = "0030-6002",
publisher = "Akademiai Kiado",
number = "14",

}

TY - JOUR

T1 - Doxorubicin + docetaxel-, illetóleg doxorubicin + cyclophosphamid-kezeléssel elérhetó eredmények távoli áttétet adó emlórákban.

AU - Szántó, J.

AU - Pintér, T.

AU - Szántó, J.

PY - 2001/4/8

Y1 - 2001/4/8

N2 - Between June 1996 and March 1998 a multinational multicentric phase III randomised comparative study was made for comparing 1. the effectiveness, 2. the adverse events and 3. the quality of life of two combinations i.e. DD versus DC. 18 patients were treated with DD and 15 patients with DC. Age, tumour stage, visceral involvement, receptor status were well matched in the two groups. Good partial remission was obtained in 10 patients treated with DD whereas only seven remissions were seen in the DC arm. Response duration was similar in the 2 arms. No difference in adverse events was observed.

AB - Between June 1996 and March 1998 a multinational multicentric phase III randomised comparative study was made for comparing 1. the effectiveness, 2. the adverse events and 3. the quality of life of two combinations i.e. DD versus DC. 18 patients were treated with DD and 15 patients with DC. Age, tumour stage, visceral involvement, receptor status were well matched in the two groups. Good partial remission was obtained in 10 patients treated with DD whereas only seven remissions were seen in the DC arm. Response duration was similar in the 2 arms. No difference in adverse events was observed.

UR - http://www.scopus.com/inward/record.url?scp=0035826525&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035826525&partnerID=8YFLogxK

M3 - Article

VL - 142

SP - 723

EP - 726

JO - Orvosi Hetilap

JF - Orvosi Hetilap

SN - 0030-6002

IS - 14

ER -